Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments is poised for long-term success with the recent announcement of favorable 2026 CMS rates, strong member retention rates of over 95%, and a proven track record of strong membership growth and SG&A leverage. With their innovative Clover Assistant platform driving improved medical cost ratios, their focus on high growth markets and attractive pricing strategies will continue to drive market share and membership growth, making them a valuable player in the healthcare technology industry.

Bears say

Clover Health Investments is facing potential headwinds in 2027 due to its transition back to 3.5-star payment and a potential flat rate year-on-year, which may impact profitability if not managed effectively. Additionally, there is uncertainty surrounding the outcome of a lawsuit appealing the star rating change and the final CMA MA advance notice. The company has a track record of profitability, but its ability to sustain this in light of these potential challenges and a competitive market is a concern. These factors contribute to a negative outlook on the stock.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.